SYGNIS AG signs non-exclusive distribution agreement with Scandinavian Biotop Oy for Finland
- Biotop is a leading Scandinavian life science distributor focused on molecular biology and cell biology
- Distribution agreement covers SYGNIS’ complete portfolio for DNA sample processing for next generation sequencing (NGS) and single cell analysis applications
Madrid, Spain and Heidelberg, Germany, June 17th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non- exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio with Biotop Oy for Finland.
Under the terms of the agreement, SYGNIS has granted Biotop the non-exclusive rights to promote, market and sell TruePrimeTM products for primer-free DNA-amplification as well as SunScriptTM thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Scandinavia.
TruePrimeTM products are based on the combination of SYGNIS’ proprietary DNA primase “TthPrimPol” and the Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
SYGNIS’ SunScriptTM product line covers a series of kits based on a proprietary reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Biotop is a specialist provider offering a broad portfolio of innovative research reagents for the wide field of molecular biology as well as cell biology applications including next generation sequencing applications to customers in Finland.
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScriptTM Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30